Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • ‘As bad as it gets’: Donald Trump’s New York business empire imperilled by fraud ruling
    • Obesity drugmaker’s expansion raises dominance worries for Denmark
    • ‘Princess of Uzbekistan’ indicted as crime syndicate boss
    • New York immigration crisis exposes tensions among Democrats
    • Armenians ‘lose motherland’ in blow to Russia’s influence abroad
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • US private equity firm takes stake in Liverpool Football Club
      • Adani switches UK auditor to firm with four partners  
      • Former Goldman and Blackstone employee charged with insider trading
      • Dealmaking languishes at decade low on private equity drought
      • Abu Dhabi group IHC sells out of two Adani companies
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • News updates from September 28: US mortgage rates hit 22-year high, Evergrande chair under ‘mandatory measures’
      • European bond market hit by Italy’s plans for higher borrowing
      • A power grab against private equity threatens the US economy
      • Fed’s ‘higher for longer’ message hits US stocks and bonds
      • Former Goldman and Blackstone employee charged with insider trading
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A power grab against private equity threatens the US economy
      • South Africans’ support for Russia is rooted in misplaced nostalgia
      • A strategy for hard-pressed consultants
      • Francis Drake’s swashbuckling spirit lives on in Kyiv’s Black Sea battles
      • The promise — and peril — of generative AI
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Success is more complicated than one exceptional individual
      • Paternity leave in finance: ‘The more men do it, the less of a big deal it becomes’
      • The activist sued by Elon Musk: ‘We have to show we will not be cowed’
      • What Burberry taught me about the marketed mind
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Why Linda Yaccarino took on the wildest job in Silicon Valley
      • Horizon 22 trumps the Shard to become London’s highest viewpoint (and it’s free)
      • Democracies need to work quicker and smarter. Here’s what that might look like 
      • Booker Prize 2023: the shortlisted titles reviewed
      • 64 Goodge Street: ‘A gorgeous room’ – restaurant review
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Abbott Laboratories

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Wednesday, 24 May, 2023
      Infant formula producers probed by FTC over bids for contracts

      Inquiry by US regulator focuses on whether manufacturers colluded in relation to programme for low-income families

      An Abbott Laboratories plant in Michigan
    • Thursday, 30 June, 2022
      US retail
      US baby formula crisis spurs debate over lack of competition

      Shortage following Abbott safety scandal draws scrutiny of sector dominated by just two companies

      Low supplies and empty shelves of baby formula at a Walmart in Carmel, Indiana, on May 14 2022
    • Tuesday, 17 May, 2022
      Lex
      Baby formula: US shortage highlights industry concentration Premium content

      Crisis points to the vulnerability of a supply chain dominated by too few producers

      The Abbott Laboratories logo
    • Friday, 3 September, 2021
      The Top LineTom Braithwaite
      Tests can help get workers back to the office

      A fresh push on fast and reliable Covid diagnostics is needed to supplement the vaccine effect

    • Wednesday, 7 October, 2020
      LexCoronavirus treatment
      Coronavirus testing: false positives Premium content

      Investors are better off putting their money on test makers rather than test processors

    • Monday, 28 September, 2020
      Coronavirus treatment
      WHO to offer 120m cheap coronavirus tests to developing world

      The $5 kit can confirm in as little as 15 minutes whether someone has Covid-19

      A nurse performs a swab test for Covid-19 on a health worker at a clinic in Johannesburg, South Africa, in May
    • Tuesday, 16 June, 2020
      Coronavirus
      UK antibody test access stokes frustration and confusion

      Consumers and doctors eager to understand who has immunity face uncertainty over testing and reliability

    • Thursday, 21 May, 2020
      Coronavirus
      Free NHS antibody tests on way after Roche and Abbott Labs deals

      And trials of 20-minute swab test to determine coronavirus infection will start next week

    • Thursday, 21 May, 2020
      Coronavirus: free to read
      Will antibody tests be our passport to normality? | Free to read

      David Crow on the complications — and consequences — of testing for coronavirus immunity

      BGUK_1931785 - Italy, ITALY - COVID-19 serological tests for individuals, microbiology and virology analysis laboratory of the PST - Scientific and Technological Pole, MultiMedica Group. Up to 400 tests per day are analyzed in the laboratory to confirm the presence of antibodies in the blood. Blood samples Pictured: GV, General View BACKGRID UK 14 MAY 2020 BYLINE MUST READ: IPA / BACKGRID UK: +44 208 344 2007 / uksales@backgrid.com USA: +1 310 798 9111 / usasales@backgrid.com *UK Clients - Pictures Containing Children Please Pixelate Face Prior To Publication*
    • Friday, 15 May, 2020
      Coronavirus
      Abbott joins Roche in winning UK approval for virus antibody test

      Public Health England gives green light to second diagnostic kit to detect past infection and potential immunity

    • Friday, 15 May, 2020
      Coronavirus
      FDA warns on rapid virus test used by White House

      ‘Early data’ show analysis might be returning false negative results in almost half of cases

    • Monday, 30 March, 2020
      Coronavirus
      J&J and Abbott flag potential vaccine and rapid test

      US healthcare groups bring hope in race to fight coronavirus pandemic

    • Thursday, 28 September, 2017
      US & Canadian companies
      AbbVie makes peace with Amgen over Humira patents
    • Friday, 14 April, 2017
      US & Canadian companies
      Abbott revises $5.3bn Alere deal to end legal spat

      US medical device makers end protracted legal dispute with deal at reduced price

      Abbott Laboratories Buys Piramal's India Unit For $3.72 Billion...Abbott Laboratories signage stands on the campus of its headquarters in Abbott Park, Illinois, U.S., on Friday, May 21, 2010. Abbott Laboratories will buy Piramal Healthcare Ltd.'s branded generic-medicine unit in India for $3.72 billion, becoming the country's biggest drugmaker and tapping into a market expected to more than double by 2015. Photographer: Tim Boyle/Bloomberg
    • Friday, 16 September, 2016
      US & Canadian companies
      J&J buys Abbott Medical for $4.3bn in eye surgery push
    • Thursday, 1 September, 2016
      LexUS & Canadian companies
      Abbott Labs/Alere: before and after

      There is an awkward dance between signing a deal and closing it

      This July 29, 2015 photo shows a sign at the Abbott Laboratories campus in Abbott Park, Ill. Abbott Laboratories will buy St. Jude Medical Inc. in a cash-stock deal that aims to strengthen the medical device maker's share of the market for cardiovascular care. (Jose M. Osorio/Chicago Tribune via AP) MANDATORY CREDIT CHICAGO TRIBUNE; CHICAGO SUN-TIMES OUT; DAILY HERALD OUT; NORTHWEST HERALD OUT; THE HERALD-NEWS OUT; DAILY CHRONICLE OUT; THE TIMES OF NORTHWEST INDIANA OUT; TV OUT; MAGS OUT; NO SALES
    • Thursday, 25 August, 2016
      LexUS & Canadian companies
      Muddy Waters-St Jude: heart attack

      Despite a series of good bets, the hedge fund’s short call on devices maker is challenged

      An artificial pacemaker (serial number 1723182) from St. Jude Medical, with electrode.
    • Thursday, 25 August, 2016
      US & Canadian companies
      Muddy Waters claims device maker vulnerable to hackers

      Hedge fund uses alleged cyber flaws to a stock falling.put pressure on St Jude Medical

      heart-rate-monitor-
    • Tuesday, 2 August, 2016
      US & Canadian companies
      Pfizer chief plays down prospect of split

      Ian Read says case for drugmaker’s break-up has become ‘more complicated’ in recent months

      A worker tests a liquid chemical inside of a laboratory at the Pfizer Inc. research and development facility in Cambridge, Massachusetts, U.S., on Monday, Oct. 26, 2015. Pfizer is expected to report quarterly earnings on October 27. Photographer: Scott Eisen/Bloomberg
    • Wednesday, 4 May, 2016
      Private equity
      Private equity closes in on $7.5bn deal for MultiPlan
    • Tuesday, 3 May, 2016
      US & Canadian companies
      Quintiles and IMS jump on the M&A bandwagon

      Merger of US groups will create $18bn clinical trials and data specialist

      health apps healthcare mobile
    • Friday, 29 April, 2016
      LexUS & Canadian companies
      M&A: back with a bang

      Cash-rich corporates are in the vanguard

      This July 29, 2015 photo shows a sign at the Abbott Laboratories campus in Abbott Park, Ill. Abbott Laboratories will buy St. Jude Medical Inc. in a cash-stock deal that aims to strengthen the medical device maker's share of the market for cardiovascular care. (Jose M. Osorio/Chicago Tribune via AP) MANDATORY CREDIT CHICAGO TRIBUNE; CHICAGO SUN-TIMES OUT; DAILY HERALD OUT; NORTHWEST HERALD OUT; THE HERALD-NEWS OUT; DAILY CHRONICLE OUT; THE TIMES OF NORTHWEST INDIANA OUT; TV OUT; MAGS OUT; NO SALES
    • Thursday, 28 April, 2016
      US & Canadian companies
      Three pharma deals worth $45bn reignite M&A boom

      Abbott, AbbVie and Sanofi announce separate purchases, taking 2016 transactions to $121bn

      Gel capsules pass through a sorting machine on the production line at a Sanofi-Aventis SA factory in Compiegne, France
    • Thursday, 28 April, 2016
      US & Canadian companies
      Abbott to buy St Jude in $25bn deal

      Acquisition of medical devices group resumes pharma merger spree

      This July 29, 2015 photo shows a sign at the Abbott Laboratories campus in Abbott Park, Ill. Abbott Laboratories will buy St. Jude Medical Inc. in a cash-stock deal that aims to strengthen the medical device maker's share of the market for cardiovascular care. (Jose M. Osorio/Chicago Tribune via AP) MANDATORY CREDIT CHICAGO TRIBUNE; CHICAGO SUN-TIMES OUT; DAILY HERALD OUT; NORTHWEST HERALD OUT; THE HERALD-NEWS OUT; DAILY CHRONICLE OUT; THE TIMES OF NORTHWEST INDIANA OUT; TV OUT; MAGS OUT; NO SALES
    • Thursday, 28 April, 2016
      Mergers & Acquisitions
      AbbVie to acquire Stemcentrx in $5.8bn deal
    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

    Tools

    PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Visual and data journalism
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today’s Newspaper (FT Digital Edition)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In